• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

    0.0940 +0.0065 (+7.43%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Jul 31, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about bioAffinity Technologies, Inc. - Warrant

    < Previous 1 2 3 4 Next >
    News headline image
    bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Closing of $3.2 Million Offering
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Pricing of $3.2 Million Offering
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Third Quarter 2025 Financial Results
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
    From bioAffinity Technologies, Inc.
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.